Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593123 · ClinicalTrials.gov registry record · Phase 2
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT02593123 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 31 participants.
The verdict
NCT02593123, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate mofetil for graft versus host disease (GVHD) prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and non-relapse mortality will be assessed. Adaptive randomization between two study arms will be performed based on T cell counts at day 60.
Interventions
- BIOLOGICAL Filgrastim
- BIOLOGICAL Sargramostim
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2022-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593123
The ClinicalTrials.gov registry entry for NCT02593123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Filgrastim is the first listed.
NCT02593123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593123 about?
NCT02593123 is a clinical study titled "Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis". Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate mofetil for graft versus host disease (GVHD) prevention following alloge...
What is the current status of trial NCT02593123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2015-11-04. Estimated completion is 2022-03-18.
What interventions are being tested in trial NCT02593123?
The interventions under investigation include: Filgrastim (BIOLOGICAL), Sargramostim (BIOLOGICAL), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT02593123?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.